Search PubMed⌕ Search

Biomedical subjects

M Matýsková

Publications and source records attributed to M Matýsková.

15 recordsLinked to original sources
PubMed2006

[The preparation of a patient with long-term anticoagulant cumarin treatment for invasive surgery].

Coumarins belong to drugs widely used and the spectrum of their use is going to grow. From this point of view and/or because the coumarins are adminstrated in patients who are treated for the other diseases--medical or surgical--at the same time, it is necessary to modify, interrupt or replace peroral anticoagulant treatment in the dependence on various aspects. It requires to compound different algorithms for given situations solution. It is always to decide, if the situation is imperative from the view of solution planed, what risk brings proposed treatment and what is the risk of anticoagulant treatment modification.

Anticoagulants↗
PubMed2006

[Complications of heparin administration].

Heparin as an indirect anticoagulant is used in the clinical practice for more than 60 years. It is an effective drug, but it has limitations. To the side effects belong the heparin resistance, risk of bleeding (haemorrhage), hypersensitivity reactions and heparin-induced osteoporosis. The low-molecular-weight heparins exhibit fewer side effects, but it is still necessary to know about them.

Anticoagulants↗
PubMed2003

[Molecular study of type 2 von Willebrand disease].

BACKGROUND: von Willebrand disease is an inherited bleeding disorders caused by mutations in the von Willebrand factor gene. We attempted to characterise the phenotype and the genotype in the first five families in Czech Republic affected by this heterogeneous disorder. METHODS AND RESULTS: The level of FVIII was measured by the one stage assay, the vWF:Ag by the immunoelectrophoresis, vWF:RiCo by aggregometry. For the vWF multimer analysis a western blot based technique was used. The vWF binding to FVIII was evaluated by the ELISA method. Two families were classified as the type 2A, one as the type 2B and two as the combined type 1/2N. Based on that knowledge, parts of the vWF gene were selected for genetic analysis. The previously described mutations Arg1374His and Gly1579Arg were identified in two families with the type 2A. In the family with type 2B a substitution Arg1308Cys was detected. In one family with the type 1/2N, two different previously described defects were found on the separate alleles of the vWF gene: a deletion of cytosine 2435 and a polymorphism Arg854Gln. Compound heterzygotes had the type 1/2N phenotype, while a carriers of the deletion had type 1 phenotype. In the second type 1/2N family, only the amino acid substitutions Thr791Me was found explaining the qualitative defect. A mutation underlying the quantitative deficiency needs to be searched for throughout the entire vWF gene. CONCLUSIONS: Based on the characterisation of the phenotype and genotype, five apparently unrelated families with the von Willebrand disease were diagnosed according to the revised classification. Our work represents laboratory basis for further studies into von Willebrand disease in Czech Republic.

Genotype↗
PubMed2002

[ABO/H blood groups and factor V Leiden].

BACKGROUND: Jick and his co-workers published in 1969 an observation showing the prevalence of blood group 0 being lower in people with thrombosis than in the healthy population. During the next years this finding was several times confirmed. The aim of our work was to answer the question on the distribution of blood groups in individuals with thrombophilia compared to the control group and whether the non-0 blood group increases the thrombosis risk in factor V Leiden carriers. We were also interested in mean values of the ProC Global test in different blood groups. METHODS AND RESULTS: Factor V Leiden, prothrombin mutation 20210A and ProC Global were examined in individuals with thrombophilia. The blood group distribution was compared in thrombophilia and control groups. The distribution was statistically different (p = 0.000). The mean value of ProC Global in the non-0 carriers was lower than in persons with blood group 0. CONCLUSION: There is a 1.76 times higher thrombosis risk (1/0.5697 = 1.76) in factor V Leiden carriers with blood group non-0 compared to blood group 0. The ProC Global mean values differ in patients with blood group 0 and in non-0 persons.

ABO Blood-Group System↗
PubMed2000

[The factor V Leiden mutation in users of hormonal contraceptives].

OBJECTIVE: To assess the frequency of factor V Leiden in oral contraceptive users and to define possible anamnestic data that could predict the presence of factor V Leiden. METHODS: Between 1997 and 1998, 583 users of oral estrogen-progestin contraceptives with no history of thrombotic disease were examined. Factor V Leiden was assessed by PCR after isolating DNA from a peripheral venous blood sample. Among other factors, such things as a family history of thromboembolic disease, myocardial infarction and/or stroke in a first-degree relative were monitored. In 448 users cardiovascular complications were evaluated during six months of oral contraceptive use. The data were analyzed using a MS Excel program. P-values were assessed by pair-tests and chi-square tests. SETTING: 1st Department of Obstetrics and Gynecology of Medical Faculty, Masaryk University, Brno. RESULTS: Factor V Leiden frequency was 6.5% in the study group. There were no differences between carriers and others in age, body weight, body mass index and blood pressure. Carriers had significantly more frequently positive family histories of thromboembolic disease or myocardial infarction or stroke. There were no cardiovascular complications observed in a group of 448 users. The positive family histories of any of the above-mentioned conditions have high specificity (97-99%) and a negative predictive value (0.94) with a low sensitivity (2.6-15.8%) in predicting factor V Leiden presence. CONCLUSION: We found a relatively high incidence of Factor V Leiden among oral contraceptive users without a history of thrombotic disease. Through a positive family history of thromboembolic disease or myocardial infarction or stroke, we can predict a Factor V Leiden presence with high specificity but low sensitivity.

Adolescent↗
PubMed1999

[Kinetics of hematopoiesis after high-dose chemotherapy and autologous peripheral stem cell transplantation].

BACKGROUND: Autologous peripheral blood stem cell transplantation (APBSCT) is gradually replacing autologous bone marrow transplantation in many clinical settings. The key question is how to evaluate the quality of grafts. We analyzed the relationship between hematopoietic reconstitution and characteristics of patients and grafts. METHODS AND RESULTS: Data from 95 APBSCTs were analyzed. Peripheral stem cells were obtained after mobilization using anti-neoplastic chemotherapy followed by Neupogen (G-CSF). After high dose chemotherapy and APBSCT, patients received Leucomax (GM-CSF). Patients were reinfused with a median of 6.1 x 10(6) (range 0.83-29.3) CD34+ cells/kg, and 25.1 x 10(4) (range 1.0-167.0) CFU-GM/kg of body weight. The median time to engraftment was 12 days (both for granulocytes 1 x 10(9)/l and platelets 50 x 10(9)/l). We found a significant correlation between the number of CD34+ cells and CFU-GM reinfused and also between their respective graft sizes and time to leukocytes, platelets, and granulocytes recovery. We did not find a significant correlation between the number of mononuclear cells reinfused and any analyzed parameter (time to engraftment, age, diagnosis, number of previous chemotherapies, type of mobilization or high-dose regimen). However, administration of preparative high-dose chemotherapy consisted of busulphan and cyclophosphamide was associated with the risk of a transient secondary graft failure. CONCLUSIONS: We conclude that the content of progenitors in PBSC grafts and time to booth leukocyte and platelet recovery are best estimated by the number of CD34+ cells (not less than 1 x 10(6)/kg) and CFU-GM (not less than 1 x 10(4)/kg). The number of mononuclear cells in an autologous PBSC graft is not suitable and useful for prediction of engraftment rate. There is probably no additional benefit of reinfusion of more than 8-10 x 10(6) CD34+ cells/kg and/or 50 x 10(4) CFU-GM/kg, because hematopoietic recovery is not more rapid.

Adolescent↗
PubMed1997

[Clinical findings in individuals with the factor V Leiden mutation].

Leiden mutation of the coagulation factor V is the most frequent known congenital risk factor of thrombophilia. The authors examined a group of 440 subjects with thrombosis in the case- or family-history. The mutation was found in 146. In 94 thrombotic manifestations were recorded in the case-history, five women were examined because of repeated abortions. 52.74% carriers of FVL had venous thrombosis of the lower extremities and pelvis in their case-history, 19.18% had pulmonary embolism in the case-history. In 27.40% during the initial manifestations of thrombosis no other risk factor of thrombosis was detected. In 10.27% the first thrombosis developed after an injury or operation. In 22.22% women the thrombosis was manifested during pregnancy or the puerperal period. Due to the high incidence of this defect screening of the resistance to activated protein C should be an integral part of examination of thrombophil conditions.

Adolescent↗
PubMed1996

[Myeloproliferative diseases].

Myeloproliferative diseases include primary polycythemia, primary thrombocytosis, primary myelofibrosis and chronic myeloid leukaemia. The average survival of patients with the former two diagnoses is more than 10 years, in the subsequent two it is only 5 years. Standard treatment of polycythemia still remains phlebotomy, only in patients with associated thrombocythemia and complications caused by it cytoreduction treatment is recommended (hydroxyurea, busulphan or interferon alpha). Patients with primary thrombocythemia due to hypofunctional thrombocytes suffer frequently from haemorrhagic and thrombotic complications. The objective of treatment is therefore to achieve a normal number of thrombocytes. Medicamentous procedures are the same as in primary polycythemia. In primary myelofibrosis and chronic myeloid leukaemia it is also necessary to reduce the pathological population in bone marrow by the above mentioned therapeutic procedures. Contrary to the former two diagnoses, the survival of patients with primary myelofibrosis is shorter and the patients need more supportive treatment. In chronic myeloid leukaemia also transplantation treatment can be used, if a suitable donor is available. The decision between classical and transplantation treatment must be made soon after establishment of the diagnosis. The objective of the following paper is to inform readers on the clinical course of different diseases, on differential diagnostic problems and changes in therapeutic procedure which have developed in recent years.

Diagnosis, Differential↗
PubMed1995

[Pleural effusion in plasmacytic leukemia].

Multiple myeloma affects predominantly osseous spaces and the close vicinity of bones. A plasmacellular exudate is rare. The authors describe the course of plasmacellular leukaemia in a 68-year-old female patient where the first symptom of the disease was anaemia and a dextrolateral pleural exudate with a cytological finding of plasma cells. The exudate disappeared after the first cycle of chemotherapy and intrapleural administration of cytostatic. After the third cycle of chemotherapy remission of the disease was recorded which was, however, short. After three months' remission (six months after establishment of the diagnosis) the disease exacerbated violently, the dextrolateral exudate reappeared and gradually the insufficiency of the infiltrated bone marrow increased. The patient died one month after the relapse of the disease. The finding of a plasmacellular exudate must be considered the sign of a very poor prognosis and in that case very aggressive treatment is indicated.

Aged↗
PubMed1995

[Venous thrombosis in relation to central venous catheters: pathogenesis, diagnosis, therapy, possibilities of prophylaxis].

Thrombosis represents one of the most frequent and severe complication of central venous catheterization. The incidence of catheter-related venous thrombosis is not well established. This complication was found in 3.3% patients in the analysis of 23 studies with central venous access devices-ports. We have found it in 3% of our patients with implanted port. The types of catheter related thrombosis are following: mural thrombosis, fibrin sheath, thrombosis on the catheter tip. Venography has been shown to be highly reliable in identification of upper-extremity deep venous thrombosis. The up-to-date possibility of treatment and prophylaxis of venous thrombosis associated with central venous catheters are reviewed in this paper.

Catheterization, Central Venous↗
PubMed1991

[Disseminated intravascular coagulation and sepsis].

The authors give an account on the relations between disseminated intravascular coagulation, sepsis and multiorgan failure. Disseminated intravascular coagulation is defined as an acquired disorder of blood clotting with an increased turnover of thrombocytes, fibrinogen and coagulation factors. The authors discuss aetiopathogenetic aspects, possibilities of laboratory diagnosis, anticoagulation and substitution therapy and prophylaxis of disseminated intravascular coagulation in septicaemia. They emphasize comprehensive treatment of septicaemias where haematological monitoring and therapy must form an integral part. In an extensive series of septic multiorgan failures the authors detected failures apparent on laboratory examination in 41% of the patients.

Disseminated Intravascular Coagulation↗
PubMed1991

[Hemophilia].

Haemophilia is one of the longest known diseases. Despite its relatively low prevalence it remains a serious medical and social problem. The authors tried to summarize in the submitted review contemporary knowledge of this hereditary disease.

Diagnosis, Differential↗
PubMedDate not supplied

[Myelodysplastic syndrome with severe thrombocytopenia and economic aspects of therapy].

On the example of a 66-year-old man the authors describe the atypical course of myelodysplastic syndrome of the type of refractory anaemia with dominating thrombocytopenia, manifested by massive haemorrhage, mostly into the digestive tract. In view of the increasing number of patients with this diagnosis, the authors attempted to elaborate the approximate costs of treatment of the condition in a medical department.

Aged↗